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The role of HER-2 expression as a prognostic factor in gastric cancer (GC) is still controversial. The aim of the study was to asses
HER-2 status, its correlations with clinicopathological parameters, and prognostic impact in GC patients. Tumor samples were
collected from 78 patients who had undergone curative surgery. In order to evaluate the intensity of immunohistochemical (IHC)
reactions two scales were applied: the immunoreactive score according to Remmele modiﬁed by the authors and standardised
Hercep test score modiﬁed for GC by Hofmann et al. The HER-2 overexpression was detected by IHC in 23 (29.5%) tumors
in Hercep test (score 2+/3+) and in 24 (30.7%) in IRS scale (IRS 4–12). The overexpression of HER-2 was associated with
poorly diﬀerentiated tumors, but this correlation was not signiﬁcant (P = 0.064). No relationship was found between HER-
2 expression and primary tumor size and degree of spread to regional lymph nodes. Both univariate and multivariate analyses
revealed that TNM stage and patient’s age were the crucial negative prognostic factors. No correlation was observed between
patient survival and expression of HER-2 estimated using both scales. This research did not conﬁrm HER-2 expression (evaluated
with immunohistochemistry) value as a prognostic tool in GC.
1.Introduction
Gastric cancer (GC) is one of the most common neoplasms
in the world. About 930000 new cases are estimated to occur
annually [1]. Despite the rapid development of several anti-
cancer drugs and the identiﬁcation of many prognostic and
predictive factors, advanced GC is still strongly associated
with a poor outcome with a median survival of 7–10 months
in patients with metastatic or unresectable disease [2]. So far,
the most important factor in prognosis and prediction for
gastriccancerpatientsistheTNMstage,whichisdetermined
by primary tumor size, degree of spread to regional lymph
nodes, and distant metastases. However, in patients with the
same stage, prognosis could be various, so further studies are
necessary to develop new prognostic factors.
HER-2 (human epidermal growth factor receptor 2)i sa
transmembrane tyrosine kinase receptor involved in devel-
opment and progression of various solid tumor types such
as breast cancer, pulmonary adenocarcinoma, and colorectal
and gastric cancer [3–5]. Although a ligand for HER-2 has
not been identiﬁed, recent studies suggest that HER-2 is the
preferred heterodimerization partner for other members of
the epidermal growth factor receptors family. The tyrosine
kinase activity of HER-2 intracellular domain triggers signal
transduction pathways, which are involved in cell prolifera-
tion, migration, apoptosis, and diﬀerentiation [6].
Although trastuzumab is currently approved for treat-
ment of HER-2 overexpressing breast cancer [7] and HER-2
overexpressing metastatic gastric cancer as a result of ToGA2 The Scientiﬁc World Journal
trial [8], there are conﬂicting results in studies of HER-2 im-
munoreactivity and its relationship to prognosis on gastric
cancer patients. However, according to ToGA trial data am-
pliﬁcationwasnotsuﬃcientenoughtoreliablydetectthepa-
tients that had a signiﬁcant beneﬁt from trastuzumab
therapy. IHC is then more predictive than FISH. Some re-
searchershavereportedthatHER-2overexpressionorampli-
ﬁcation is strongly associated with a poor outcome in gastric
cancer [9–11], but other studies have failed to ﬁnd any as-
sociation with the prognosis [12, 13]. In this study, the ex-
pression of HER-2 in gastric cancer was investigated by im-
munohistochemistry. The correlations between HER-2 para-
meters of expression and clinicopathological parameters and
overall survival were analyzed.
2.Methodology
2.1. Patients and Tissue Specimens. Seventy-eight patients
with histologically conﬁrmed adenocarcinoma of the stom-
ach operated on with curative intent (R0) entered the study.
The group of patients consisted of 54 males and 24 females
with ages ranging between 37 and 84 years old (mean age:
62 years old). The stage of tumors was assessed according
to the 5th ed. of TNM Classiﬁcation of Malignant Tumors
[14] (stage I: 25 patients (32%); II: 18 (23%); III: 17 (22%);
IVM0: 18 (23.1%). According to Lauren’s classiﬁcation: 19
(24%) cases were intestinal, 44 (56.%) diﬀused and 15
(19.%) were of a mixed type. All patients underwent elective
total gastrectomy and D2 lymphadenectomy with curative
intent (the mean number of dissected lymph nodes was 19).
The adjuvant chemotherapy was administered in 53 cases
of tumors inﬁltrating beyond the muscularis propria or in
patients with lymph node involvement. The followup was
scheduled every 3 months for the ﬁrst 2 years and then every
6 months. Chest X-ray, abdominal sonography, CT scan
as well as clinical and endoscopic examinations were per-
formed. The information about overall survival were ob-
tained from Lower-Silesian Regional Cancer Registry. The
data were collected in a retrospective manner.
The tissue samples were ﬁxed in 10% buﬀered formalin
and embedded in paraﬃn. In each case, hematoxylin- and
eosin-stained preparations were subjected to histopathologi-
cal evaluation by two pathologists.
2.2.Immunohistochemistry. Formalin-ﬁxed,paraﬃne mbed-
dedtissuewasfreshlycut(4μm).Thesectionsweremounted
onsuperfrostslides(MenzelGl¨ aser,Germany),dewaxedwith
xylene, and gradually hydrated. The activity of endogenous
peroxidase was blocked by 5min exposure to 3% H2O2.
All the studied sections were boiled for 15min at 250W
in the Antigen Retrieval Solution (DakoCytomation, Den-
mark). Then, immunohistochemical reactions were per-
formedusingtherabbitantihumanantibody detectingHER-
2 (optimally prediluted) (DakoCytomation, Denmark). The
tested sections were incubated with antibodies for 1h at
room temperature. The subsequent incubations involved
biotinylated antibodies (15min, room temperature) and a
streptavidin-biotinylated peroxidase complex (15min, room
temperature) (LSAB+, HRP, DakoCytomation, Denmark).
NovaRed (Vector Laboratories, UK) was used as a chro-
mogen (10min, at room temperature). All the sections were
counterstained with Meyer’s hematoxylin. In every case,
control reactions were included, in which speciﬁc antibody
was substituted by the Primary Mouse Negative Control
(DakoCytomation, Denmark).
2.3. Evaluation of Reaction Intensity. The intensity of
immunohistochemical reactions was estimated indepen-
dently by two pathologists. In doubtful cases a reevaluation
was performed using a double-headed microscope and
staining was discussed until a consensus was achieved. It is
supposed that application of breast cancer scoring to gastric
cancer may produce an up to 50% false-negative rate if IHC
is used. Thus in order to evaluate the HER-2 expression,
the Remmele scale (IRS) [15] modiﬁed by the authors and
standardised Hercep test score modiﬁed for GC by Hofmann
et al. were applied (Table 1)[ 16]. In IRS scale the intensity of
colorreactionandpercentageofpositivecellsweretakeninto
account. The score represented a product of points given for
the evaluated characters and it ranged from 0 to 12 (Table 1).
Cases with expression of 0 to 3 in IRS scale and with score
0 to 1+ according to Hofmann et al.’s criteria were treated
as cases without overexpression (Table 2). It is well known
that patients with gastric cancer have a heterogeneous HER-
2expression.IntratumoralheterogeneityofHER2expression
maypotentiallycontributetoinaccurateassessmentofHER2
status. There is evidence that tumor heterogeneity is more
common in gastric cancer (4.8%) than in breast cancer
(1.4%) [16]. We observed 9% cases with heterogenous HER-
2immunoreactivity.Therefore,insomeinstitutionstheeval-
uation of HER-2 expression in the immunohistochemical
staining is carried out using several sections of tissue sample.
In our study single slide from large representative resection
specimen for each cancer case was analyzed and 10% cutoﬀ
for the number of reactive cells was retained.
2.4. Statistical Analysis. Statistical analyses were performed
using the Statistica 9.1 software (StatSoft Inc., Tulsa, OK,
USA) and R language and environment for statistical com-
puting (R Foundation for Statistical Computing, Vienna,
Austria, http://www.R-project.org/). Chi2 and Spearman
rank correlation were used to analyze associations between
immunohistochemical parameters of HER-2 expression and
clinicopathological features. The overall survival rate was
estimated by the Kaplan-Meier method. Multivariate anal-
yses (Cox proportional hazard regression models) were also
performed to assess the prognostic value of HER-2 expres-
sion and other clinicopathological features.
3. Results
3.1. HER-2 Expression in Gastric Cancer. The HER-2 over-
expression was detected in 23 (29.5%) tumors in Hercep
test (IHC 2+/3+) and in 24 (30.7%) in IRS scale (IRS 4–
12) (Figure 1). Lack of HER-2 expression was found in
35 cases (44.9%). In all samples membrane localization ofThe Scientiﬁc World Journal 3
Table 1: Two procedures for evaluation of HER-2 expression.
Percentage of positive cells IRS (Immunoreactive Score) modiﬁed by authorsa
Points
Points Intensity of reaction
No positive cells 0 No reaction 0
<25% positive cells 1 Weak colour reaction 1
25–50% positive cells 2 Moderate intensity 2
51–75% positive cells 3 Intense reaction 3
>75% positive cells 4
Consensus recommendations on HER-2 scoring for gastric cancerb
Deﬁnition Score
No reactivity or membranous reaction in <10% of cells 0
Faint complete or partial membranous reactivity in >10% of cells 1+
Moderate complete or basolateral membranous reactivity in >10% of cells 2+
Strong complete or basolateral membranous reactivity in >10% of cells 3+
aIRS score (Immunoreactive Score) according to Remmele and Stegner [15] modiﬁed by authors
bHercep test criteria modiﬁed by Hofmann et al. [16]f o rg a s t r i cc a n c e r .
Table 2: Parameters of HER-2 immunoreactivity.
Immunohistochemical
parameters Score/points N (%) Interpretation
Hercep test scorea
0 35 (44.9) Negative
1+ 20 (25.6) Negative
2+ 17 (21.8) Overexpression
3+ 6 (7.7) Overexpression
Percentage of positive
HER-2 cancer cells (%)b
0 35 (44.9)
1 12 (15.4)
2 10 (12.8)
3 10 (12.8)
4 11 (14.1)
Intensity of HER-2
reaction (I)c
0 35 (44.9)
1 15 (19.2)
2 21 (26.9)
37 ( 9 . 0 )
HER-2 IRSd
0-1 42 (53.8) Negative
2-3 12 (15.4) Negative
4–8 20 (25.6) Overexpression
9–12 4 (5.2) Overexpression
aHercep test criteria modiﬁed by Hofmann et al. [16]f o rg a s t r i cc a n c e r .
bPercentageofHER-2positivegastriccancercells(%)accordingtoRemmele
and Stegner [15] modiﬁed by authors.
cIntensity of immunohistochemical reaction in cancer cells (I) according to
Remmele and Stegner [15] modiﬁed by authors.
dIRS score (Immunoreactive Score) according to Remmele and Stegner [15]
modiﬁed by authors.
HER-2 in gastric cancer cells was dominantly observed, but
cytoplasmic topography was also described (Table 2).
3.2. Association between HER-2 Immunoreactivity and Clin-
icopathological Parameters. The overexpression of HER-2
was associated with poorly diﬀerentiated tumors, but this
correlation was marginally signiﬁcant (P = 0.064). Interest-
ingly, the statistical analysis revealed a signiﬁcant association
between the percentage of HER-2 positive gastric cancer cells
and the presence of ulceration in clinical material (P =
0.035). No relationship (Table 3)w a sf o u n db e t w e e nH E R -
2 overexpression and primary tumor size, degree of spread
to regional lymph nodes, type of Lauren’s classiﬁcation and
inﬂammatory inﬁltration of the tumor (tumor inﬁltrating
lymphocytes).
3.3. HER-2 Expression and Patients Survival. The survival
analysis performed with Kaplan-Meier method revealed
that tumor size at diagnosis (pT3, pT4), regional lymph
nodes metastases, and patient’s age covariated with negative
prognostic signiﬁcance (P = 0.028, P = 0.015 and P =
0.0048, resp.). No correlation was observed between patient
survival and overexpression of HER2 (Figure 2). We only
observed a tendency towards worse prognosis among 11
patients with highest HER-2 IRS (8–12 IRS); however, this
correlation was not statistically signiﬁcant (P = 0.071). The
multivariate analysis (Table 4) conﬁrmed the unfavorable
prognostic signiﬁcance of advanced age (P = 0.014),
advanced pT stage (P = 0.027), nodal involvement (P =
0.027), and lack of prognostic value of HER-2 expression
parameters.
4. Discussion
The study has described the expression of HER-2, detected
byimmunohistochemistryininvasivegastriccancer.Theim-
munoreactivity of HER-2 did not reveal any correlation
between histopathological parameters, such as Lauren’s
classiﬁcation type or gastric cancer grading. Interestingly,
only one signiﬁcant relationship between the presence of
ulceration and the percentage of positive HER-2 cancer cells
was observed. The survival analysis did not conﬁrm the
prognostic signiﬁcance of HER-2 overexpression in gastric
cancer patients.
HER-2 reactivity has been studied extensively in gastric
cancer in order to correlate it to clinicopathological features
and prognosis, due to the potential using of trastuzumab4 The Scientiﬁc World Journal
(a) (b)
(c) (d)
Figure 1: Immunohistochemical expression of HER-2 in gastric cancer tissue: (a) Hercept test: 1+, IRS: 4, ×200; (b) Hercep test: 2+, IRS: 8,
×200; (c) HercepTest: 3+, IRS: 12, ×200; (d) Hercep test: 3+, IRS: 12, ×200.
Table 3: Correlations between HER-2 expression and clinicopathological parameters.
Clinicopathological parameters Hercep testa,b HER-2%a,c HER-2 Ia,d HER-2 IRSa,e
Tumor size (pT) 0.211 0.454 0.389 0.193
Nodal metastases (pN+) 0.945 0.736 0.702 0.750
Grading 0.064 0.212 0.189 0.202
Lauren’s classiﬁcation 0.505 0.835 0.692 0.554
Agef 0.570 0.935 0.693 0.693
Ulceration 0.672 0.035 0.162 0.074
Tumor inﬁltrating lymphocytes 0.839 0.889 0.717 0.852
aP value of Chi2 test.
bHercep test criteria modiﬁed by Hofmann et al. [16]f o rg a s t r i cc a n c e r .
cPercentage of HER-2-positive gastric cancer cells (%) according to Remmele and Stegner [15] modiﬁed by authors.
dIntensity of immunohistochemical reaction in cancer cells (I) according to Remmele and Stegner [15] modiﬁed by authors.
eIRS score (ImmunoReactive Score) according to Remmele and Stegner [15] modiﬁed by authors.
fSpearman’s rank correlation.
as an adjuvant chemotherapy [3, 9–12]. In our previous
study based on immunohistochemical evaluation of 396
breast cancer specimens, HER-2/neu overexpression has
been documented in 18% of invasive cancer cases and has
been associated with a poor prognosis [17]. Other authors
documented HER-2 overexpression in 10–34% of breast
cancer cases [4]. Favorable clinical results with anti-HER-
2/neu therapy in breast cancer have led to the analysis of
its expression in other solid tumors, such as ovarian, lung,
colon and gastric cancers [5, 9, 11, 12, 18]. A number of
studies have analyzed HER-2/neu immunoexpression in GC,
but the clinical signiﬁcance of its expression is not fully clear
yet. Some authors documented that HER-2/neu appears to
be an important prognostic factor in GC [3, 9, 12, 16],
however, the literature is conﬂicting at this point, and other
studies did not reveal any correlation between HER-2/neu
overexpression and a poor prognosis [13, 19] .T h er a t eo f
HER-2/neu positivity in GC is estimated to be between 15%
and 20% [1, 3, 9, 12, 16, 20].
This study conﬁrmed that parameters of TNM classiﬁ-
cation are the most important prognostic factors in gastric
cancer. However, we did not observe a statistically signiﬁcant
correlation between HER-2 overexpression and Lauren’s
classiﬁcation, which is also known as a signiﬁcant prognosticThe Scientiﬁc World Journal 5
0 20 40 60 80 100 120
0
0.2
0.4
0.6
0.8
1
0–1
2–3
(a)
0 20 40 60 80 100 120
0.2
0.4
0.6
0.8
1
0–2
3–4
(b)
0 20 40 60 80 100 120
0
0.2
0.4
0.6
0.8
1
0–1
2–3
(c)
0 20 40 60 80 100 120
0
0.2
0.4
0.6
0.8
1
−0.2
0–3
4–6
8–12
(d)
Figure 2: Kaplan-Meier curves for survival and expression of HER-2 in studied group of 78 gastric cancer patients: No correlation was
observed between Hercep test score (P = 0.454) (a), percentage of HER-2 positive gastric cancer cells (P = 0.717) (b), intensity of
immunohistochemical reaction (P = 0.397) (c) and IRS rate (P = 0.071) (d).
Table 4: Multivariate Cox proportional hazard regression analysis
of HER-2 expression and clinicopathological parameters inﬂuence
on patients overall survival.
Clinicopathological parameters P-value
Age 0.014
Nodal metastases (pN) 0.003
Tumor size (pT) 0.027
Hercep test scorea 0.775
Percentage of positive HER-2 cancer cellsb 0.741
Intensity of HER-2 color reaction (I)c 0.859
HER-2 IRSd 0.321
aHercep test criteria modiﬁed by Hofmann et al. [16]f o rg a s t r i cc a n c e r .
bPercentage of HER-2-positive gastric cancer cells (%) according to
Remmele et al. [15] modiﬁed by authors.
cIntensity of immunohistochemical reaction in cancer cells (I) according to
Remmele and Stegner [15] modiﬁed by authors.
dIRSscore(ImmunoReactiveScore)accordingtoRemmeleandStegner[15]
modiﬁed by authors.
factor. It was observed a distinct tendency between HER-
2 expression and Lauren’s type of cancer, because 40% of
intestinal type is characterized by elevated level of HER-
2 expression and only 20% of diﬀu s et y p ew e r eH E R -
2 overexpressed, but the diﬀerence was statistically not
signiﬁcant. Similar results were published by Gravalos and
Jimenof [6], because they revealed relationship between
HER-2 overexpression and Lauren’stype, butthis correlation
was also statistically not signiﬁcant. Interestingly, Kang et al.
[21] reported that HER-2 overexpression correlated with the
histological type according to Lauren’s classiﬁcation with
statistical signiﬁcance (34% intestinal type; 6% diﬀuse).
Park et al. [9] having used FISH in the detection of HER-
2 ampliﬁcation observed that intestinal-type cancers were
associated with a higher HER-2 ampliﬁcation rate than
diﬀuse-type cancers (P<0.05).
Our research did not conﬁrm the value of HER-2
overexpression in prognosis on GC patients. Similar results
were observed by Tateishi et al. [13] and Sasano et al. [19],
whodid not ﬁnd any relationship between HER-2 expression
andprognosis.However,thevastmajorityofstudiesreported
a direct correlation between HER-2 overexpression and GC
patients survival. Park et al. [9] revealed that tumors with
HER-2ampliﬁcation(demonstratedinFISH)exhibitedpoor6 The Scientiﬁc World Journal
mean survival. Surprisingly, the above mentioned study
showed that HER-2 ampliﬁcation was more common in the
intestinal type of GC, which is usually associated with better
prognosis. Staining intensity of HER-2 was also strong-
ly correlated with unfavorable outcome in Zhang’s et al.
study. Survival curves, computed according to the method
of Kaplan-Meier, showed that HER-2 overexpression in 102
gastric cancer patients was signiﬁcantly correlated with de-
creased survival [11].
5. Conclusions
The signiﬁcance of HER-2 overexpression in GC and its
impact on survival is controversial. This research did not
conﬁrm value of HER-2 expression detected by immunohis-
tochemistry as a prognostic tool in GC. In spite of this accu-
rate assessment of HER-2/neu status is essential to determine
which patients might beneﬁt from the monoclonal antibody
therapy. This study conﬁrmed that parameters of TNM
classiﬁcation are the most important prognostic factors in
gastric cancer.
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